Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra Health Care REIT, Inc. SBRA has an almost 7% dividend yield.

Supporting this view, Truist Securities analyst Michael Lewis, on March 18, raised the price target on the stock from $17 to $18. The company posted better-than-expected earnings and sales results on Feb. 19 for the fourth quarter.

Joshua Brown of Ritholtz Wealth Management named Kinsale Capital Group, Inc. KNSL as his final trade.

Kinsale Capital Group announced Thursday that it will release financial results for the first quarter after the closing bell on April 24. Analysts expect the company to report quarterly earnings at $3.22 per share, down from $3.5 per share in the year-ago period. Kinsale Capital projects quarterly revenue of $425.73 million for the recent quarter, compared to $372.79 million a year earlier.

Don't forget to check out our premarket coverage here

Joseph M. Terranova of Virtus Investment Partners picked Amgen Inc. AMGN.

Adding support to his choice, Amgen, on Thursday, announced that the U.S. Food and Drug Administration approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).

Price Action:

• Sabra Health Care gained 1.7% to close at $17.65 on Thursday.
• Kinsale Capital shares rose 1.4% to close at $498.60 during Thursday's session.
• Amgen shares gained 1.4% to settle at $309.85 on Thursday.

Check This Out:

• Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs

Photo: Shutterstock